Fulcrum therapeutics announces recent business highlights and financial results for third quarter 2023

― completed enrollment in the phase 3 reach trial of losmapimod in facioscapulohumeral muscular dystrophy (fshd); expect to report topline data in the fourth quarter of 2024 ―
FULC Ratings Summary
Quant
FULC Quant Ranking
Sector
Industry
Quant Rating
Quant Score